Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome

Br J Haematol. 2022 Jun;197(6):e82-e85. doi: 10.1111/bjh.18103. Epub 2022 Mar 11.
No abstract available

Keywords: early assessment; flow cytometry; measurable residual disease; multiple myeloma; outcome.

Publication types

  • Letter

MeSH terms

  • Flow Cytometry
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasm, Residual
  • Treatment Outcome